Scholars Central

Conference abstract

Antibacterials: Past, Present ? and Future?

Authors: Nafsika H. Georgopapadakou

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

T he last novel antibacterial class to win approval was discovered over 25 years ago. During the next decade, genomics, high-throughput screening and combinatorial chemistry dominated antibacterial drug di scovery with little success. Th is, coupled with the intrinsic low return on investment of antibacterials, led most pharmaceutical companies to abandon the fi eld out-licensing the few compounds still in development to small biotechnology companies. At the same time, the ready availability of antibacterials for human and animal health worldwide led to alarming levels of resistance in both gram-positive and gram-negative bacteria. Th e situation is certain to deteriorate in the coming years and has brought a sense of urgency to the discovery of new/improved antibacterials. Th e success of daptomycin, tigecycline and linezolid ? and the resurgence of polymyxin ? despite toxicity liabilities underscore the commercial viability of antibacterials. One approach likely to s ucceed is targeting bacterial enzymes using insights and compounds acquired from other therapeutic ar eas. Another approach is using PK/PD (or manipulating them via formulations) to reduce the toxicity of eff ective but toxic antibacterials to acceptable levels for their re-introduction in the clinic

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Nafsika H. Georgopapadakou”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels